-

Flatiron Health Names New Chief Business, Technology, and Product Leaders

Michael Bierl, Allison Candido, and Kate Estep assume expanded roles to drive innovation and scale.

NEW YORK--(BUSINESS WIRE)--Flatiron Health is pleased to announce three significant appointments to its Executive Team, reflecting the critical, enterprise-level responsibilities these leaders have assumed and the company’s evolving direction. Michael Bierl will serve as Chief Business Officer, Allison Candido will serve as Chief Technology Officer, and Kate Estep will serve as Chief Product Officer. With decades of combined experience, Bierl, Candido, and Estep bring the leadership and expertise needed to accelerate Flatiron’s strategy and deliver integrated data, intelligence, and point-of-care solutions that can transform cancer care globally.

Michael, Allie, and Kate’s expanded roles enable us to operate with greater clarity, coordination, and focus as we fundamentally transform how we deliver on our mission to improve and extend lives for every person with cancer.

Share

“These appointments reflect where Flatiron is headed as we build an integrated global platform that defines the future of oncology,” said Nathan Hubbard, Chief Executive Officer at Flatiron Health. “Michael, Allie, and Kate’s expanded roles enable us to operate with greater clarity, coordination, and focus as we fundamentally transform how we deliver on our mission to improve and extend lives for every person with cancer."

Michael Bierl, Chief Business Officer
Bierl joined Flatiron in 2019 and has been instrumental in shaping and scaling the company's Global Evidence business and expanding Flatiron's impact, including building and leading the company's European presence. In his role as Chief Business Officer, Bierl leads Flatiron's global commercial, scientific, clinical, operational, and customer-facing teams—reflecting how Flatiron increasingly serves customers and partners through integrated evidence solutions.

Allison Candido, Chief Technology Officer
Candido has been a foundational leader at Flatiron since 2014, bringing deep technical vision and operational excellence to all of her contributions. As Chief Technology Officer, she will continue to lead Flatiron's Engineering organization as the technology evolves its use of AI to unlock data at unprecedented scale and meet the most complex needs of customers in the oncology ecosystem.

Kate Estep, Chief Product Officer
Since joining Flatiron in 2018, Estep has earned a reputation as a deeply trusted leader, known for connecting strategy, product thinking, and customer needs across Flatiron's Point of Care and Global Evidence businesses. As Chief Product Officer, Estep will drive the evolution of Flatiron's Point of Care and Global Evidence product suites, unifying how customers across oncology providers and life sciences leverage data and AI solutions to generate intelligence that enables better decisions for life sciences partners and clinicians, accelerating progress in cancer care.

Bierl, Candido, and Estep join Cal Brouilette, Chief Financial Officer, and Julia Morton, Chief Operating Officer, on Flatiron's Executive Team, all reporting to the CEO Nathan Hubbard.

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Contacts

Media Contact
Nina Toor
press@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Nathan Hubbard
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Media Contact
Nina Toor
press@flatiron.com

Social Media Profiles
More News From Flatiron Health

Flatiron Health Announces Research at ISPOR Europe 2026 Advancing Global Oncology Evidence for Health Technology Assessment

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced seven research abstracts to be presented at ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2026 conference, taking place November 8–11 in Vienna, Austria. The research examines how real-world evidence can support health technology assessment (HTA), how oncology findings may translate across countries, and how transparent validation can support the use of AI-derived data in research. Flatiron will also h...

Flatiron Health Announces Research at ESMO Congress 2026 Examining Cancer Treatment and Outcomes Across Global Markets

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced that four research abstracts will be presented as e-posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The research examines how cancer treatments are used in everyday practice, how patient outcomes vary, and where additional evidence could help inform care across the United States, Germany, Japan, and the United Kingdom. Spanning colorectal, lung, and prostate cancer,...

Flatiron Health Expands Telescope to International Real-World Data, Bringing AI-Powered Oncology Insights to a Global Database of More Than Six Million Patients

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced the international expansion of Flatiron Telescope, its AI-powered oncology intelligence platform, extending its capabilities to datasets from the UK, Germany, and Japan. Building on Telescope’s launch earlier this year, the expansion brings a global dimension to how life sciences teams ask and answer oncology questions, drawing on Flatiron’s real-world database of more than six million patients. The expansion will enable teams to explor...
Back to Newsroom